Buradasınız

Anasayfa » Content

Neonatal Sitomegalovirus Hepatiti ve Kolestazda Antiviral Tedavi

Antiviral Therapy In Neonatal Cytomegalovirus Hepatitis And Cholestasis

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2005

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Neonatal hepatitis refers to a heterogenous group of disorders that result in a some what similar morphologic change in the liver of an infant less than 3 months of age, in response to various insults, including cytomegalovirus infection. Neonatal hepatitis is responsible for approximately 40% of the cases of infants with cholestasis. Cytomegalovirus may infect and replicate in both hepatocytes and cholangiocytes. It may be cause latent or acut cholestatic or chronic hepatitis, including cirrhosis in immunocompatent infant too. It must be discussed treatment choice with ganciclovir particularly in severe cases. In our center, 12 cases with CMV neonatal hepatitis were diagnosed in betwen January 2003-January 2005. Group 1 was consisted of seven babies who were treated with ganciclovir during 21 days. Five cases who were not given antiviral treatment were described as group 2. Physical examination, biochemical tests, antiviral serology were done both groups at the time of diagnosis and repeated at the third month. This study revealed that ganciclovir treatment was safe and efficient in the cholestatic hepatitis cases.
Bookmark/Search this post with
Abstract (Original Language): 
Neonatal hepatit, değişik nedenlerle 3 aydan küçük süt çocuklarının karaciğerinde benzer morfolojik değişikliklere yol açan hastalıkların grubudur. Sitomegalovirus enfeksiyonu da neonatal hepatit nedenlerinden biridir. Kolestatik süt çocuklarının yaklaşık % 40’ının etiyolojisinde neonatal hepatit vardır. Sitomegalovirus hepatosit ve kolanjiositleri enfekte ederek çoğalır. İmmün yetersizliği olmayan süt çocu- ğunda da latent; akut kolestatik veya kronik hepatite yol açabilir. Özellikle ağır olgularda Gansiklovir tedavi şansı değerlendirilmelidir. Ocak 2003-Ocak 2005 arasında CMV neonatal hepatit tanısı alan 12 olguda çalışma yapıldı. Grup 1, 7 bebekten oluşup 21 gün süreyle gansiklovir tedavisi uygulandı. Grup 2, 5 bebekten oluşup antiviral tedavi almadı. Her 2 gruptan çocukların başlangıç ve 3 ay sonra fizik muayene, biyokimya, serolojik değerleri karşılaştırılarak gansiklovir tedavisinin kolestetik hepatitte uygun ve güvenilir olduğu sonucuna varıldı.
FULL TEXT (PDF): 
PDF icon arastirmax-neonatal-sitomegalovirus-hepatiti-kolestazda-antiviral-tedavi.pdf
  • 2
103-106
  • Turkish

REFERENCES

References: 

1. Denson LA. Other Viral Infections. In: Walker,WA
(eds).Pediatric Gastrointestinal Disease. 4
th
Edition. Ontario:
BC Decker Inc;2004. 1170-1178.
2. Varanı S, Landini MP. Cytomegalovirus as a hepatotropic
virus. Clin Lab 2002;48:39-44.
3. Rosenthal P. Neonatal Hepatitis and Congenital Infections. In:
Suchy F (ed).Liver Disease in Children. 2
nd
Edition.
Philadelphia: Lippincott William &Wilkins; 2001. 239-252.
4. Cohen JI, Corey GR. Cytomegalovirus infection in the normal
host. Medicine (Baltimore) 1985;64:100-14.
5. Zuschke CA, Herrera JL, Pettyjohn FS. Cytomegalovirus
hepatitis mimicking an acute exacerbation of chronic hepatitis
B. South Med J 1996; 89:1213-6.
6. Yousfi MM, Douglas DD. Other Hepatitis Viruses. In:
Zakim&Boyer (eds) Hepatology. 4
th
Edition. Philadelphia:
Saunders 2003. 1063-1072.
7. Shuster E. Monoclonal antibody for rapid laboratory detection
of cytomegalovirus infections. Characterization and diagnostic
application. Mayo Clin Proc 1985; 60(9): 577-585.
8. Mendez JC, Espy MJ, Smith TF, et al. Evaluation of PCR
primers for early diagnosis of cytomegalovirus infection
following liver transplantation. J Clin Microbiol 1998; 36(2)
526-530.
9. Chang MH, Huang HH, Huang ES, et al. Polymerase chain
reaction to detect human cytomegalovirus in livers of infants
with neonatal hepatitis. Gastroenterology 1992; 103(3): 1022.
10. Berenberg W, Nankervis G. Long-term follow-up of
cytomegalic inclusion disease of infancy. Pediatrics 1970;46:
403-410.
11. Dressler S, Linder D. Noncirrhotic portal fibrosis following
neonatal cytomegalic inclusion disease. J Pediatr 1978; 93:
887-888.
12. Vancikova Z, Kucerova T. Perinatal cytomegalovirus
hepatitis: To treat or not to treat with ganciclovir. J Pediatr
Child Health 2004; 40(8): 444-8.
13. Balfour HJ. Antiviral drugs. N Engl J Med 1999; 340(16):
1255-1268.
14. Nigro G, Krzysztofiak A. Ganciclovir therapy for
cytomegalovirus-associated liver disease in immunocompetent
or immunocompromised children. Arch Virol 1997; 142: 573-
80.
15. Serna-Higuera C. Acute cholestatic hepatitis by
cytomegalovirus in an immunocompetent patient resolved
with ganciclovir. J Clin Gastroenterol 1999; 29(3): 276-7.
16. Pehlivanoğlu E. Ganciclovir therapy for cytomegalovirus
infection in infants. J Pediatr 1994; 125(4): 670-1.
17. Fernandez TP, Lopez Serrano P. Diagnostic and therapeutic
approach to cholestatic liver disease. Rev Esp Enferm Dig
2004; 96(1): 60-73.

Thank you for copying data from http://www.arastirmax.com